ClinicalTrials.Veeva

Menu

Pulmonary Hypertension Prevention in Hemodialysis

B

Baruch Padeh Medical Center

Status

Unknown

Conditions

Chronic Kidney Disease

Study type

Observational

Funder types

Other

Identifiers

NCT01350687
farid.CTIL

Details and patient eligibility

About

Pulmonary hypertension is a new complication described in hemodialysis patients. in the last year these patients were treated by calcium carbonate orally to control serum phosphor. Calcium phosphor deposits in pulmonary artery can explain this phenomena. The investigators want to investigate the new phosphor non calcium containing agents in hemodialysis patients and to measure the pulmonary pressure.

Full description

The investigators will measure pulmonary blood pressure before and after treatment with new phosphor binders, non calcium containing.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Hemodialysis Patients without fistula

Exclusion criteria

  • Heart Disease

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems